Oric Pharmaceuticals (ORIC) Income from Continuing Operations (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Income from Continuing Operations came in at 140296000.0 in Q1 2026, down 214.38% YoY from 122655930.1 in Q1 2025, and down 308.07% on a QoQ basis from 34380000.0 in Q4 2025.
Oric Pharmaceuticals (ORIC) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Income from Continuing Operations data on file, last reported at 140296000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 214.38% year-over-year to 140296000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 386652000.0 (up 4.62% YoY) and the FY2025 annual result came in at 355200000.0, down 12.64% from the prior year.
- Income from Continuing Operations eased to 140296000.0 in Q1 2026, from 34380000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 25574000.0 in Q2 2022 to a low of 212475000.0 in Q4 2024.
- A 5-year average of 83360058.82 and a median of 59210000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 428.54% — and 2025, when it soared 83.82%.
- Tracing ORIC's Income from Continuing Operations over 5 years: stood at 123108000.0 in 2022, then tumbled by 33.03% to 163766000.0 in 2023, then declined by 29.74% to 212475000.0 in 2024, then soared by 83.82% to 34380000.0 in 2025, then slumped by 308.07% to 140296000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 140296000.0 (Q1 2026), 34380000.0 (Q4 2025), and 116540000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - | -115.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -115.56 Mn |
| Mar 31, 2026 | -140.30 Mn |
| Dec 31, 2025 | -34.38 Mn |
| Sep 30, 2025 | -116.54 Mn |
| Jun 30, 2025 | -95.44 Mn |
| Mar 31, 2025 | -44.63 Mn |
| Dec 31, 2024 | -212.48 Mn |
| Sep 30, 2024 | -89.08 Mn |
| Jun 30, 2024 | -59.21 Mn |
| Mar 31, 2024 | -118.61 Mn |
| Dec 31, 2023 | -163.77 Mn |
| Sep 30, 2023 | -43.70 Mn |
| Jun 30, 2023 | -54.56 Mn |
| Mar 31, 2023 | -37.82 Mn |
| Dec 31, 2022 | -123.11 Mn |
| Sep 30, 2022 | -28.50 Mn |
| Jun 30, 2022 | -25.57 Mn |
| Mar 31, 2022 | -29.44 Mn |
| Dec 31, 2021 | -23.29 Mn |
| Sep 30, 2021 | -66.20 Mn |